{"result": {"id": "3f9e9c81-f173-408d-aa51-f10c394dfa25", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Cardiovascular Research and Guidelines Community\",\n    \"summary\": \"This community is centered around cardiovascular research, with key entities including researchers like Böhm M, Collins R, and Baigent C, as well as prestigious journals such as The Lancet and the New England Journal of Medicine. The European Society of Cardiology plays a pivotal role in this community, collaborating with various organizations to develop guidelines for cardiovascular disease prevention and treatment. The relationships within this community highlight a strong focus on collaborative research, guideline development, and the dissemination of high-impact medical findings.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the community's significant contributions to cardiovascular medicine, including groundbreaking research and the development of influential clinical guidelines.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of The Lancet and New England Journal of Medicine\",\n            \"explanation\": \"The Lancet and the New England Journal of Medicine are central to this community, serving as key platforms for publishing high-impact cardiovascular research. These journals have published studies by prominent researchers such as Böhm M, Swedberg K, and Perkovic V, covering a wide range of topics from heart failure treatments to renal denervation outcomes. Their rigorous peer-review processes and global reach make them authoritative sources in medical science. [Data: Entities (2149, 2924), Relationships (3068, 3241, 3569, 3567, 3568, +more)]\"\n        },\n        {\n            \"summary\": \"Collaborative Guideline Development by the European Society of Cardiology\",\n            \"explanation\": \"The European Society of Cardiology (ESC) is a cornerstone of this community, collaborating with organizations like the European Society of Hypertension and the European Atherosclerosis Society to develop comprehensive guidelines for cardiovascular disease management. These guidelines influence clinical practice across Europe and beyond, ensuring high standards of care. The ESC's work with researchers such as A.R. Lyon and Piepoli MF underscores its commitment to advancing cardiology through evidence-based practice. [Data: Entities (2722, 3007, 4413), Relationships (2867, 3151, 3648, 3649, 3650, +more)]\"\n        },\n        {\n            \"summary\": \"Significant Contributions of Key Researchers\",\n            \"explanation\": \"Researchers like Böhm M, Collins R, and Baigent C have made significant contributions to cardiovascular medicine, focusing on areas such as heart failure, vascular disease prevention, and the effects of aspirin. Their collaborative studies and meta-analyses have provided valuable insights into treatment strategies and risk factors, influencing both clinical practice and further research. [Data: Entities (2840, 3000, 2640), Relationships (3142, 2803, 3122, 2802, +more)]\"\n        },\n        {\n            \"summary\": \"Innovative Clinical Trials and Studies\",\n            \"explanation\": \"The community is marked by its involvement in innovative clinical trials and studies, such as the SYMPLICITY HTN-3 trial and the RADIANCE-HTN trials, which explore new treatments for resistant hypertension. Researchers like Bhatt DL, Kandzari DE, and Azizi M are at the forefront of these efforts, contributing to the advancement of interventional cardiology. [Data: Entities (2920, 2921, 2922), Relationships (3058, 3061, 3064, 3070, 3071, +more)]\"\n        },\n        {\n            \"summary\": \"Focus on Preventive Cardiology and Rehabilitation\",\n            \"explanation\": \"Preventive cardiology and rehabilitation are key themes within this community, with organizations like the European Association for Cardiovascular Prevention & Rehabilitation playing a vital role. Research by Naci H and colleagues comparing exercise and antihypertensive medications highlights the community's interest in non-pharmacological interventions for cardiovascular health. [Data: Entities (3007, 2613), Relationships (2776, 2780, 2781, +more)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560525, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 843, "prompt_tokens": 6945, "total_tokens": 7788, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1600}, "prompt_cache_hit_tokens": 1600, "prompt_cache_miss_tokens": 5345}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n2840,B?HM M,\"Böhm M is a researcher primarily focused on cardiovascular studies, with contributions spanning various aspects of heart failure and related treatments. His work includes investigating heart rate as a risk factor in chronic heart failure, as well as examining the effects of treatments such as aliskiren on post-discharge mortality and heart failure readmissions in hospitalized patients. Additionally, Böhm M has been involved in research on renal denervation and its long-term outcomes, highlighting his broader interest in interventional and pharmacological approaches to managing cardiovascular conditions. His multidisciplinary research underscores his expertise in both clinical and therapeutic aspects of heart failure and hypertension.\",3\n2149,LANCET,\"**The Lancet** is a prestigious international medical journal renowned for publishing high-impact research, reviews, and systematic analyses across a wide range of health topics. It covers diverse medical fields, including cardiovascular diseases, hypertension, global health, psychiatric genomics, and metabolic disorders.  \n\nThe journal has published significant studies such as a systematic analysis of mortality, morbidity, and risk factors in China, as well as research on isolated systolic hypertension. It has also featured clinical trials, including a phase 3 study on a microsomal triglyceride transfer protein inhibitor and a randomized trial comparing aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis. Additionally, **The Lancet** has explored dietary interventions for metabolic syndrome and salt sensitivity in China, as well as meta-analyses on blood-pressure-lowering treatments.  \n\nNotably, in 2011, the journal published a study on the combination of aliskiren and amlodipine as an initial treatment strategy for hypertension control. Recognized for its rigorous peer-review process and influential contributions to medical science, **The Lancet** remains a leading authority in disseminating cutting-edge research across multiple disciplines.\",34\n3069,SWEDBERG K,A researcher involved in studies on Ivabradine and outcomes in chronic heart failure>,2\n2164,CHEN J,A researcher involved in a study on metabolic syndrome and salt sensitivity of blood pressure in China>,1\n2165,GU D,A researcher involved in a study on metabolic syndrome and salt sensitivity of blood pressure in China>,1\n2166,HUANG J,A researcher involved in a study on metabolic syndrome and salt sensitivity of blood pressure in China>,1\n2615,MILLWOOD IY,,1\n2909,TOWNSEND RR,Townsend RR is a researcher involved in the SPYRAL HTN-OFF MED trial,1\n3657,CROSS-DISORDER GROUP OF THE PSYCHIATRIC GENOMICS CONSORTIUM,\"Research group identifying shared risk loci for psychiatric disorders\"\"\",1\n4693,CUCHEL M,\"Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\"\"\",1\n4694,MEAGHER EA,\"Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\"\"\",1\n4695,DU TOIT THERON H,\"Researcher involved in the phase 3 study of microsomal triglyceride transfer protein inhibitor\"\"\",1\n4715,MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR,\"Therapeutic agent studied for homozygous familial hypercholesterolaemia\"\"\",1\n2722,EUROPEAN SOCIETY OF CARDIOLOGY,\"The **European Society of Cardiology (ESC)** is a leading professional organization in Europe dedicated to cardiovascular medicine and research. It serves as a key authority in developing clinical guidelines for a wide range of cardiovascular conditions, including cardio-oncology, hypertension (in collaboration with the European Society of Hypertension), and lipid disorders. The ESC plays a pivotal role in advancing cardiology through research, education, and evidence-based practice, ensuring high standards of care across Europe and beyond. As the primary professional body for cardiology in the region, it fosters collaboration among healthcare professionals to improve cardiovascular health outcomes.\",10\n3007,EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION,An organization focused on cardiovascular disease prevention and rehabilitation in Europe,1\n3599,EUROPEAN HEMATOLOGY ASSOCIATION,\"A medical society focused on hematology research and practice\"\"\",1\n3601,INTERNATIONAL CARDIO-ONCOLOGY SOCIETY,\"An organization dedicated to the intersection of cardiovascular disease and cancer\"\"\",1\n3607,A.R. LYON,\"Researcher involved in developing ESC cardio-oncology guidelines\"\"\",1\n4413,EUROPEAN ATHEROSCLEROSIS SOCIETY,The European Atherosclerosis Society is a professional organization focused on the study and treatment of atherosclerosis and related conditions,1\n3000,BAIGENT C,\"**BAIGENT C** is a researcher primarily known for their work in the field of vascular disease prevention, with a focus on the role of aspirin in both primary and secondary prevention. They have contributed to meta-analyses examining the efficacy and safety of aspirin in this context. Additionally, BAIGENT C has been involved in the development of clinical guidelines, serving as a co-author of the **2019 ESC/EAS Guidelines for the management of dyslipidaemias**, demonstrating their broader expertise in cardiovascular and metabolic disorders. Their research contributions highlight a multidisciplinary approach to understanding and managing vascular and lipid-related diseases.\",4\n2640,COLLINS R,\"**Collins R** is a researcher primarily focused on cardiovascular disease prevention and treatment. Their work encompasses several key areas, including the study of **non-vitamin K antagonist oral anticoagulants (NOACs)** in patients with **atrial fibrillation**, as well as the role of **aspirin** in both **primary and secondary prevention of vascular disease**. Collins R has also contributed to **meta-analyses** examining the effects of **aspirin use in vascular disease prevention** and the relationship between **blood pressure and cardiovascular outcomes**. Their research demonstrates a broad expertise in cardiovascular medicine, spanning pharmacological interventions, risk assessment, and large-scale evidence synthesis.\",6\n2665,MACMAHON S,\"MACMAHON S is a researcher known for their involvement in significant clinical and analytical studies related to diabetes, hypertension, and cardiovascular outcomes. They contributed to the ADVANCE trial, which focuses on diabetes and hypertension, and have also participated in meta-analyses examining the relationship between blood pressure and cardiovascular outcomes. Their work spans both clinical research and large-scale data analysis in the field of cardiovascular and metabolic health.\",2\n2987,BLACKWELL L,Blackwell L is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy,4\n2664,PETO R,\"Researcher involved in meta-analyses on blood pressure and cardiovascular outcomes\"\"\",1\n3481,PERKOVIC V,\"**PERKOVIC V** is a researcher primarily associated with studies related to the renin-angiotensin system inhibitors and their implications in medical research. Additionally, PERKOVIC V has been involved in significant research on **canagliflozin** and its effects on renal outcomes in patients with **type 2 diabetes**, contributing to advancements in understanding treatment options for diabetic kidney disease. Their work spans both pharmacological interventions and broader investigations into cardiovascular and renal health.\",2\n2924,NEW ENGLAND JOURNAL OF MEDICINE,\"The *New England Journal of Medicine (NEJM)* is a prestigious and premier medical journal renowned for publishing high-impact clinical and research studies across a wide range of medical disciplines. It is recognized for featuring landmark clinical trials and cutting-edge research, including significant findings in areas such as diabetes, cardiovascular outcomes, and hypertension. For instance, NEJM has published controlled trials on innovative treatments like renal denervation for resistant hypertension. As a leading authority in medical literature, the journal consistently delivers rigorously peer-reviewed content that shapes clinical practice and advances global healthcare knowledge.\",5\n2605,EUROPEAN HEART JOURNAL,\"The **European Heart Journal** is a prominent cardiology journal that publishes a wide range of research and guidelines related to cardiovascular health. It has released key publications, including guidelines on exercise and cardiovascular disease, as well as consensus statements from the European Atherosclerosis Society in 2020 and 2021. Additionally, the journal has featured long-term outcome studies derived from the global SYMPLICITY registry, contributing to advancements in the understanding and treatment of cardiovascular conditions. Through these publications, the **European Heart Journal** serves as an authoritative resource for clinicians, researchers, and healthcare professionals in the field of cardiology.\",5\n2608,PELLICCIA A,\"Author of ESC guidelines on sports cardiology\"\"\",1\n2986,EMBERSON J,Emberson J is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy,2\n3514,WIVIOTT SD,Wiviott SD is a researcher or author associated with studies on dapagliflozin and cardiovascular outcomes in type 2 diabetes>,1\n3517,ZINMAN B,Zinman B is a researcher or author associated with studies on empagliflozin and cardiovascular outcomes in type 2 diabetes>,1\n3606,M. AZIZI,\"Researcher who studied home blood-pressure monitoring in patients receiving sunitinib\"\"\",1\n4676,ICOSAPENT ETHYL,\"A drug studied for cardiovascular risk reduction in hypertriglyceridemia\"\"\",2\n2617,BR J SPORTS MED,\"A British journal focusing on sports medicine and exercise-related research\"\"\",1\n2613,NACI H,\"NACI H is a researcher focused on studying the effects of exercise and medication on blood pressure. Their work includes conducting meta-analyses to compare the impacts of exercise and antihypertensive medications, aiming to provide evidence-based insights into their relative effectiveness in managing blood pressure.\",4\n2644,SALCHER-KONRAD M,\"Researcher involved in meta-analysis comparing exercise and antihypertensive medications\"\"\",1\n2645,DIAS S,\"Researcher involved in meta-analysis comparing exercise and antihypertensive medications\"\"\",1\n2904,BHATT DL,\"**BHATT DL** is a researcher involved in multiple clinical studies across different therapeutic areas. Notably, Bhatt DL has contributed to research on **icosapent ethyl** for the treatment of **hypertriglyceridemia**, as well as participated in trials investigating **renal denervation** as a potential therapy for **resistant hypertension**. These studies highlight Bhatt DL's involvement in cardiovascular and metabolic research, spanning both pharmacological and interventional approaches.\",4\n2920,SYMPLICITY HTN-3 TRIAL,The SYMPLICITY HTN-3 trial is a randomized controlled trial on renal denervation for resistant hypertension,1\n2905,KANDZARI DE,Kandzari DE is a researcher involved in multiple trials on renal denervation for hypertension,3\n2919,SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM,The SPYRAL HTN Global Clinical Trial Program studies renal denervation in the absence and presence of antihypertensive medications,2\n2908,MAHFOUD F,Mahfoud F is a researcher involved in multiple studies on renal denervation and its effects,3\n3543,ACCOMPLISH,ACCOMPLISH is a randomised controlled trial investigating the effects of body size and hypertension treatments on cardiovascular event rates,4\n3547,WEBERMA,WeberMA is a researcher involved in the ACCOMPLISH trial,1\n3548,JAMERSONK,JamersonK is a researcher involved in the ACCOMPLISH trial,1\n3549,BAKRISGL,BakrisGL is a researcher involved in the ACCOMPLISH trial and other hypertension-related studies,1\n2402,MANN JF,\"MANN JF is a researcher known for his work in nephrology and cardiovascular risk studies. He is associated with the ONTARGET study, which investigated renal outcomes involving treatments with telmisartan and ramipril. Additionally, his research focuses on the relationship between albuminuria and cardiovascular risk in both diabetic and nondiabetic individuals. His contributions span clinical trials and observational studies in these fields.\",3\n2755,SCHMIEDERRE,\"SchmiederRE is a researcher involved in the ONTARGET study on cardiovascular risks and treatments.\"\"\",1\n2756,MCQUEEN M,\"McQueen M is a researcher who contributed to the ONTARGET study on renal outcomes.\"\"\",1\n2925,AMERICAN HEART JOURNAL,The American Heart Journal published the rationale and design for the SPYRAL HTN studies,1\n2911,AZIZI M,Azizi M is a researcher involved in the RADIANCE-HTN SOLO and TRIO trials,3\n2921,RADIANCE-HTN SOLO,\"RADIANCE-HTN SOLO is a multicentre, international, single-blind, randomised, sham-controlled trial on endovascular ultrasound renal denervation\",1\n2922,RADIANCE-HTN TRIO,\"RADIANCE-HTN TRIO is a randomised, multicentre, single-blind, sham-controlled trial on ultrasound renal denervation for hypertension resistant to a triple medication pill\",1\n2985,MIHAYLOVA B,Mihaylova B is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy,2\n3011,PIEPOLI MF,A researcher involved in European guidelines on cardiovascular disease prevention,3\n3026,HOES AW,Researcher involved in European cardiovascular prevention guidelines,1\n3027,AGEWALL S,Researcher involved in European cardiovascular prevention guidelines,1\n3013,GAZIANO JM,A researcher involved in trials studying aspirin for reducing vascular events,3\n3030,BROTONS C,Researcher involved in aspirin trials for cardiovascular prevention,1\n3031,COPPOLECCHIA R,Researcher involved in aspirin trials for cardiovascular prevention,1\n3019,HINDRICKS G,A researcher involved in ESC guidelines for atrial fibrillation diagnosis and management,3\n3042,POTPARA T,Researcher involved in ESC atrial fibrillation guidelines,1\n3043,DAGRES N,Researcher involved in ESC atrial fibrillation guidelines,1\n3381,XIE X,\"XIE X is a researcher known for their work in cardiovascular studies, particularly focusing on the effects of renin-angiotensin system inhibitors and intensive blood pressure lowering on cardiovascular outcomes. Their research contributes to understanding the therapeutic impacts of these interventions in managing cardiovascular health.\",2\n2680,PATEL A,A researcher involved in the ADVANCE trial on diabetes and hypertension,1\n3334,SAMMPRIS,\"The SAMMPRIS trial studied aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis\"\"\",2\n3342,DERDEYN CP,\"Derdeyn CP was involved in the SAMMPRIS trial on intracranial artery stenosis treatment\"\"\",1\n3346,SYST-EUR STUDY,\"A study examining the prevention of dementia with antihypertensive treatment\"\"\",2\n3372,FORETTE F,\"Researcher involved in the Syst-Eur study on dementia prevention\"\"\",1\n3433,EUROPEAN SOCIETY FOR VASCULAR SURGERY,Medical society focused on vascular surgery>,2\n3456,ABOYANS V,Researcher developing ESC vascular guidelines>,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n3068,B?HM M,LANCET,Böhm M published research in The Lancet journal,37\n3241,SWEDBERG K,LANCET,Swedberg K published research in Lancet,36\n2443,LANCET,CHEN J,Chen J's research on metabolic syndrome and salt sensitivity was published in Lancet,35\n2444,LANCET,GU D,Gu D's research on metabolic syndrome and salt sensitivity was published in Lancet,35\n2445,LANCET,HUANG J,Huang J's research on metabolic syndrome and salt sensitivity was published in Lancet,35\n2769,LANCET,MILLWOOD IY,Millwood IY published genetic evidence on alcohol and vascular disease in The Lancet,35\n3067,TOWNSEND RR,LANCET,Townsend RR published research in The Lancet journal,35\n3696,CROSS-DISORDER GROUP OF THE PSYCHIATRIC GENOMICS CONSORTIUM,LANCET,Published the group's genome-wide analysis,35\n4528,CUCHEL M,LANCET,Cuchel M was a researcher in a study published in Lancet,35\n4529,MEAGHER EA,LANCET,Meagher EA was a researcher in a study published in Lancet,35\n4530,DU TOIT THERON H,LANCET,Du Toit Theron H was a researcher in a study published in Lancet,35\n4531,LANCET,MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR,Study of MTP inhibitor was published in The Lancet,35\n2867,EUROPEAN SOCIETY OF CARDIOLOGY,EUROPEAN SOCIETY OF HYPERTENSION,Both organizations collaborate to provide hypertension treatment guidelines.,31\n3151,EUROPEAN SOCIETY OF CARDIOLOGY,EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION,Collaborated on guidelines for cardiovascular disease prevention,11\n3648,EUROPEAN SOCIETY OF CARDIOLOGY,EUROPEAN HEMATOLOGY ASSOCIATION,Collaborated on developing cardio-oncology guidelines,11\n3649,EUROPEAN SOCIETY OF CARDIOLOGY,INTERNATIONAL CARDIO-ONCOLOGY SOCIETY,Collaborated on developing cardio-oncology guidelines,11\n3650,EUROPEAN SOCIETY OF CARDIOLOGY,A.R. LYON,Contributed to ESC cardio-oncology guidelines,11\n4254,EUROPEAN SOCIETY OF CARDIOLOGY,EUROPEAN ATHEROSCLEROSIS SOCIETY,These organizations collaborate on guidelines for the management of lipid disorders,11\n3142,BAIGENT C,COLLINS R,\"BAIGENT C and COLLINS R collaborated on research focused on the role of aspirin in the primary and secondary prevention of vascular disease. They were co-authors of a meta-analysis examining the effectiveness of aspirin use in preventing vascular disease, consolidating evidence from multiple studies to assess its impact. Their work contributed to a broader understanding of aspirin's role in vascular health.\",10\n2803,COLLINS R,MACMAHON S,Collaborated on blood pressure meta-analyses,8\n3122,BLACKWELL L,BAIGENT C,Baigent C and Blackwell L collaborated on research about aspirin in the primary and secondary prevention of vascular disease,8\n2802,COLLINS R,PETO R,Collaborated on blood pressure meta-analyses,7\n3569,PERKOVIC V,NEW ENGLAND JOURNAL OF MEDICINE,Perkovic V published research in New England Journal of Medicine,7\n2773,EUROPEAN HEART JOURNAL,PELLICCIA A,Pelliccia A authored ESC guidelines published in this journal,6\n3121,EMBERSON J,BLACKWELL L,Emberson J and Blackwell L collaborated on research about the effects of LDL cholesterol lowering with statin therapy,6\n3567,WIVIOTT SD,NEW ENGLAND JOURNAL OF MEDICINE,Wiviott SD published research in New England Journal of Medicine,6\n3568,ZINMAN B,NEW ENGLAND JOURNAL OF MEDICINE,Zinman B published research in New England Journal of Medicine,6\n3647,NEW ENGLAND JOURNAL OF MEDICINE,M. AZIZI,Published research on home blood-pressure monitoring in sunitinib patients,6\n4514,ICOSAPENT ETHYL,BEMPEDOIC ACID,Both are drugs studied for cardiovascular risk reduction,6\n2776,BR J SPORTS MED,NACI H,Naci H published research in the British Journal of Sports Medicine comparing exercise and antihypertensive medications,5\n2780,NACI H,SALCHER-KONRAD M,Collaborated on meta-analysis comparing exercise and antihypertensive medications,5\n2781,NACI H,DIAS S,Collaborated on meta-analysis comparing exercise and antihypertensive medications,5\n3058,BHATT DL,SYMPLICITY HTN-3 TRIAL,Bhatt DL is a researcher involved in the SYMPLICITY HTN-3 trial,5\n3061,KANDZARI DE,SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM,Kandzari DE is a researcher involved in the SPYRAL HTN Global Clinical Trial Program,5\n3064,MAHFOUD F,SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM,Mahfoud F is a researcher involved in the SPYRAL HTN Global Clinical Trial Program,5\n3584,ACCOMPLISH,WEBERMA,WeberMA is a researcher involved in the ACCOMPLISH trial,5\n3585,ACCOMPLISH,JAMERSONK,JamersonK is a researcher involved in the ACCOMPLISH trial,5\n3586,ACCOMPLISH,BAKRISGL,BakrisGL is a researcher involved in the ACCOMPLISH trial,5\n2899,MANN JF,SCHMIEDERRE,Mann JF and SchmiederRE collaborated on the ONTARGET study.,4\n2900,MANN JF,MCQUEEN M,Mann JF and McQueen M co-authored research on renal outcomes.,4\n3063,KANDZARI DE,AMERICAN HEART JOURNAL,Kandzari DE published research in the American Heart Journal,4\n3070,AZIZI M,RADIANCE-HTN SOLO,Azizi M is a researcher involved in the RADIANCE-HTN SOLO trial,4\n3071,AZIZI M,RADIANCE-HTN TRIO,Azizi M is a researcher involved in the RADIANCE-HTN TRIO trial,4\n3119,MIHAYLOVA B,EMBERSON J,Mihaylova B and Emberson J collaborated on research about the effects of LDL cholesterol lowering with statin therapy,4\n3164,PIEPOLI MF,HOES AW,Co-authors on European cardiovascular prevention guidelines,4\n3165,PIEPOLI MF,AGEWALL S,Co-authors on European cardiovascular prevention guidelines,4\n3168,GAZIANO JM,BROTONS C,Co-authors on aspirin trial for cardiovascular prevention,4\n3169,GAZIANO JM,COPPOLECCHIA R,Co-authors on aspirin trial for cardiovascular prevention,4\n3182,HINDRICKS G,POTPARA T,Co-authors on ESC atrial fibrillation guidelines,4\n3183,HINDRICKS G,DAGRES N,Co-authors on ESC atrial fibrillation guidelines,4\n3541,XIE X,PERKOVIC V,Co-authors of research on renin-angiotensin system inhibitors,4\n2820,PATEL A,MACMAHON S,Collaborated on the ADVANCE trial,3\n3455,SAMMPRIS,DERDEYN CP,Derdeyn CP was involved in the SAMMPRIS trial,3\n3469,SYST-EUR STUDY,FORETTE F,Led the Syst-Eur study on dementia prevention,3\n3524,EUROPEAN SOCIETY FOR VASCULAR SURGERY,ABOYANS V,Developed joint guidelines with ESVS,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_ac0f1b568550366549ae65ca8b80cac0ebdf4457b17fb56cabdebb41f53e3ee1_v2"}